Vipergen news
Zagreb, Croatioa, September 3-7, 2023 Vipergen presents a poster entitled: Efficient Cell-Based DEL Screening https://www.efmc-asmc.org/
IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry Read More »
Cambridge, US, November 1-2, 2023 Vipergen gives a talk entitled DELs in Cells https://www.oxfordglobal.co.uk/discovery-us/
COPENHAGEN, Denmark, June 15, 2022—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new
COPENHAGEN, Denmark, April 4, 2022 — Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies.
COPENHAGEN, Denmark, December 21, 2021 – Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions. Under the terms of the agreement, Vipergen
COPENHAGEN, Denmark, November 23, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that
COPENHAGEN, Denmark, November 15, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with the allergy company ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL
Limburgerhof, Germany, and Copenhagen, Denmark, October 21, 2021 – Farmers worldwide are facing the challenge of feeding a growing population while reducing the impact of agriculture on the environment. BASF partners with Vipergen, a global leader in research services, to apply their technology to discover new active ingredients for sustainable crop protection products more efficiently
COPENHAGEN, Denmark, September 14, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost. Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost
COPENHAGEN, Denmark, May 17, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery service agreement with Anavo Therapeutics. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads
